<ul><li>Amsterdam-based LUMICKS secures €20M in venture debt agreement from the European Investment Bank (EIB).</li><li>The investment aims to accelerate drug discovery for cancer through LUMICKS' high-throughput cell avidity platform.</li><li>The platform enables direct measurement of immune cell binding with cancer cells, optimizing therapy development.</li><li>LUMICKS plans to utilize the funding to advance research and development and deliver impactful therapies in the immunotherapy space.</li></ul>

Amsterdam’s LUMICKS gets €20M from European Investment Bank (EIB) to accelerate drug discovery for cancer

Discover more